In addition to Cabot Brown, 7 other GWPH executives reported Sell trades in the last month. Following Cabot Brown’s last GWPH Sell transaction on March 03, 2021, the stock climbed by 0.6%.
Based on GW Pharma’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $148 million and GAAP net loss of -$29,147,000. In comparison, last year the company earned revenue of $109 million and had a GAAP net loss of $24.95 million. The company has a one-year high of $217.50 and a one-year low of $73.52. Currently, GW Pharma has an average volume of 408.73K.
Based on 11 analyst ratings, the analyst consensus is Moderate Buy with an average price target of $217.13, reflecting a -0.8% downside.
The insider sentiment on GW Pharma has been negative according to 92 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
GW Pharmaceuticals Plc is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It offers its cannabinoid product, Epidiolex oral solution CV, a pharmaceutical formulation of cannabidiol (CBD) focusing on the treatment of seizures associated with tuberous sclerosis complex. The company was founded by Geoffrey William Guy and Brian Whittle in 1998 and is headquartered in Cambridge, the United Kingdom.